Publications by authors named "Joo Yoon Han"

Background: Primary prevention implantable cardioverter defibrillator (ICD) reduce all-cause mortality by reducing sudden cardiac death. There are conflicting data regarding whether patients with more advanced heart failure derive ICD benefit owing to the competing risk of nonsudden death.

Methods: We performed a patient-level meta-analysis of New York Heart Association (NYHA) class II/III heart failure patients (left ventricular ejection fraction ≤35%) from 4 primary prevention ICD trials (MADIT-I, MADIT-II, DEFINITE, SCD-HeFT).

View Article and Find Full Text PDF

Background: No precise tools exist to predict appropriate shocks in patients with a primary prevention ICD. We sought to identify characteristics predictive of appropriate shocks in patients with a primary prevention implantable cardioverter defibrillator (ICD).

Methods: Using patient-level data from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), we identified patients with any appropriate shock.

View Article and Find Full Text PDF

Objectives: The aim of this study was to determine if the benefit of implantable cardioverter-defibrillators (ICDs) is modulated by medical comorbidity.

Background: Primary prevention ICDs improve survival in patients at risk for sudden cardiac death. Their benefit in patients with significant comorbid illness has not been demonstrated.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of implantable cardioverter-defibrillators (ICDs) for patients with chronic kidney disease and heart failure, using a meta-analysis from several trials.
  • Approximately 36.3% of the 2,867 patients included had reduced kidney function (eGFR < 60 mL/min/1.73 m²), with results showing that ICDs significantly reduced mortality only in patients with better kidney function (eGFR ≥ 60), while showing no benefit for those with lower kidney function.
  • Limitations included the small sample size of patients with very low eGFR and potential inconsistencies in trial measurement methods that could affect results.
View Article and Find Full Text PDF